CBV regimen: Difference between revisions
No edit summary |
No edit summary |
||
| Line 5: | Line 5: | ||
{{SK}} BCNU/CTX/VP-16; Carmustine/Cyclophosphamide/Etoposide; CBV | {{SK}} BCNU/CTX/VP-16; Carmustine/Cyclophosphamide/Etoposide; CBV | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to [[cyclophosphamide|cyclophosphamide (Cytoxan)]], [[Carmustine|carmustine (BCNU)]], and [[Etoposide|etoposide (VP-16)]], three drugs in a [[chemotherapy regimen]] commonly given to [[lymphoma]] patients in conjunction with [[stem cell]] | {{PAGENAME}} refers to [[cyclophosphamide|cyclophosphamide (Cytoxan)]], [[Carmustine|carmustine (BCNU)]], and [[Etoposide|etoposide (VP-16)]], three drugs in a [[chemotherapy regimen]] commonly given to [[lymphoma]] patients in conjunction with [[stem cell|stem cell therapy]].<ref>Skeel, Roland T. ''Handbook of Cancer Chemotherapy, 6th Edition''. Philadelphia: Lipincott, Williams, & Wilkins, 2003. Page 172-3, Table 5.4: "Common preparative regimens for high-dose therapy without total-body irradiation."</ref> | ||
==Regimen== | ==Regimen== | ||
{{chemo|C|Cyclophosphamide}} | |||
{{chemo|B|Carmustine (BCNU)}} | |||
{{chemo|V|Etoposide (VP-160)}} | |||
==Indications== | ==Indications== | ||
*Acute leukemia<ref name="pmid3545428">{{cite journal| author=Zander AR, Culbert S, Jagannath S, Spitzer G, Keating M, Larry N et al.| title=High dose cyclophosphamide, BCNU, and VP-16 (CBV) as a conditioning regimen for allogeneic bone marrow transplantation for patients with acute leukemia. | journal=Cancer | year= 1987 | volume= 59 | issue= 6 | pages= 1083-6 | pmid=3545428 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3545428 }} </ref> | *[[leukemia|Acute leukemia]]<ref name="pmid3545428">{{cite journal| author=Zander AR, Culbert S, Jagannath S, Spitzer G, Keating M, Larry N et al.| title=High dose cyclophosphamide, BCNU, and VP-16 (CBV) as a conditioning regimen for allogeneic bone marrow transplantation for patients with acute leukemia. | journal=Cancer | year= 1987 | volume= 59 | issue= 6 | pages= 1083-6 | pmid=3545428 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3545428 }} </ref> | ||
==References== | ==References== | ||
Latest revision as of 14:43, 11 March 2015
|
WikiDoc Resources for CBV regimen |
|
Articles |
|---|
|
Most recent articles on CBV regimen Most cited articles on CBV regimen |
|
Media |
|
Powerpoint slides on CBV regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on CBV regimen at Clinical Trials.gov Clinical Trials on CBV regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on CBV regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on CBV regimen Discussion groups on CBV regimen Patient Handouts on CBV regimen Directions to Hospitals Treating CBV regimen Risk calculators and risk factors for CBV regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for CBV regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: BCNU/CTX/VP-16; Carmustine/Cyclophosphamide/Etoposide; CBV
Overview
CBV regimen refers to cyclophosphamide (Cytoxan), carmustine (BCNU), and etoposide (VP-16), three drugs in a chemotherapy regimen commonly given to lymphoma patients in conjunction with stem cell therapy.[1]
Regimen
CCyclophosphamide
BCarmustine (BCNU)
VEtoposide (VP-160)
Indications
References
- ↑ Skeel, Roland T. Handbook of Cancer Chemotherapy, 6th Edition. Philadelphia: Lipincott, Williams, & Wilkins, 2003. Page 172-3, Table 5.4: "Common preparative regimens for high-dose therapy without total-body irradiation."
- ↑ Zander AR, Culbert S, Jagannath S, Spitzer G, Keating M, Larry N; et al. (1987). "High dose cyclophosphamide, BCNU, and VP-16 (CBV) as a conditioning regimen for allogeneic bone marrow transplantation for patients with acute leukemia". Cancer. 59 (6): 1083–6. PMID 3545428.